BioMarin Reports Mixed Q4/FY25 Results, Withdraws ROCTAVIAN, Issues Strong 2026 EPS Guidance

summarizeSummary

BioMarin Pharmaceutical Inc. reported mixed Q4 and full-year 2025 financial results, marked by strong revenue growth in key products but a significant GAAP net loss in Q4 due to the voluntary withdrawal of ROCTAVIAN from the market and associated $240 million in charges. The company also provided optimistic 2026 Non-GAAP EPS guidance and highlighted the strategic acquisition of Amicus Therapeutics.

check_boxKey Events

• Q4 and Full-Year 2025 Financial Results

  Reported Q4 2025 total revenues of $875 million (up 17% year-over-year) and full-year 2025 total revenues of $3.2 billion (up 13%). VOXZOGO revenue grew 31% in Q4 and 26% for the full year, while Enzyme Therapies revenue increased 13% in Q4 and 9% for the full year. However, the company reported a GAAP Net Loss of $47 million for Q4 2025, compared to a GAAP Net Income of $125 million in Q4 2024.

• ROCTAVIAN Withdrawn from Market

  BioMarin announced the voluntary withdrawal of ROCTAVIAN from the market, resulting in approximately $240 million in charges during Q4 2025. These charges included a $119 million inventory write-off and $118 million in long-lived asset impairments, significantly impacting GAAP net income.

• Strong 2026 Financial Guidance

  Provided 2026 full-year guidance (excluding post-close contribution from Amicus acquisition), projecting total revenues between $3.325 billion and $3.425 billion. Non-GAAP Diluted EPS is guided to be between $4.95 and $5.15, a substantial increase from $3.15 in 2025, indicating strong expected profitability.

• Amicus Therapeutics Acquisition Update

  Reiterated the definitive agreement to acquire Amicus Therapeutics, expected to close in Q2 2026. This acquisition is anticipated to significantly accelerate and diversify revenues with the addition of Galafold and Pombiliti + Opfolda.

auto_awesomeAnalysis

This 8-K is highly important as it provides a comprehensive update on BioMarin's financial performance, strategic direction, and pipeline. The voluntary withdrawal of ROCTAVIAN from the market, resulting in $240 million in charges and a GAAP net loss for Q4 2025, is a significant negative event, indicating a product failure and impacting immediate profitability. However, this is partially offset by robust double-digit revenue growth from core products like VOXZOGO and Enzyme Therapies, demonstrating underlying business strength. The company's 2026 financial guidance, particularly the substantial increase in Non-GAAP Diluted EPS, suggests a strong outlook for future profitability, excluding the Amicus acquisition. The pending acquisition of Amicus Therapeutics is a strategic move aimed at accelerating and diversifying future revenues, positioning the company for long-term growth despite the immediate setback from ROCTAVIAN. Investors should monitor the integration of Amicus and the execution of the 2026 guidance.